Publication Information

Basic Information

Access and Citation

AI Researcher Chatbot

Get quick answers to your questions about the article from our AI researcher chatbot

Primary Location

Authors

Topics

Keywords

Related Works

Title: $RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN CORRELATES WITH TUMOR VOLUME IN PATIENTS WITH INCREASED PROSTATE SPECIFIC ANTIGEN
Abstract: No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2001RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN CORRELATES WITH TUMOR VOLUME IN PATIENTS WITH INCREASED PROSTATE SPECIFIC ANTIGEN DAVID J. GROSSKLAUS, SCOTT B. SHAPPELL, SHIVA GAUTAM, JOSEPH A. SMITH, and MICHAEL S. COOKSON DAVID J. GROSSKLAUSDAVID J. GROSSKLAUS , SCOTT B. SHAPPELLSCOTT B. SHAPPELL , SHIVA GAUTAMSHIVA GAUTAM , JOSEPH A. SMITHJOSEPH A. SMITH , and MICHAEL S. COOKSONMICHAEL S. COOKSON View All Author Informationhttps://doi.org/10.1097/00005392-200102000-00024AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the relationship between the ratio of free-to-total prostate specific antigen (PSA) and prostate pathology, including grade, stage and tumor volume, among patients with prostate cancer who underwent radical prostatectomy. Materials and Methods: We prospectively analyzed 54 consecutive patients with prostate cancer who underwent radical prostatectomy and in whom frozen serum was available for assessment of free-to-total PSA ratio. Pathological review was done with whole mount sections, and total tumor volume was determined by planimetry. Comparison between free-to-total PSA ratio and pathological parameters was performed using the Pearson correlation coefficient. Results: Among the 54 patients mean total and free-to-total PSA ratio were 5.81 and 14.2 ng./ml., respectively, and free-to-total PSA ratio directly correlated with prostate volume (p = 0.037), and inversely correlated with Gleason score (p = 0.012) and extracapsular disease (p = 0.0074). Furthermore, there was a significant relationship between free-to-total PSA ratio and pathological stage pT2a/b in 39 cases versus pT3a/b in 15 (p = 0.005). Overall, there was no correlation between free-to-total PSA ratio and tumor volume. However, among 37 patients with an increased PSA, defined as greater than 4.0 ng./ml., a significant inverse relationship between free-to-total PSA ratio and tumor volume was identified (p = 0.01). Among this subset there was only a weak correlation with prostate volume (p = 0.049). Conclusions: Our findings suggest that free-to-total PSA ratio may be predictive of tumor biology among those patients with a total PSA of greater than 4 ng./ml. as evidenced by good correlation with tumor grade and volume. This finding appears to be independent of prostate volume. These preliminary results suggest the need for additional studies among patients with an increased PSA designed to evaluate the potential role of free-to-total PSA ratio in combination with traditional clinical variables in the prediction of prostate cancer pathology. References 1 : Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998; 279: 1542. Google Scholar 2 : Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA1995; 274: 1214. Google Scholar 3 : Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology1996; 48: 55. Google Scholar 4 : Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol1998; 159: 5. Link, Google Scholar 5 : Percentage of free serum prostate-specific-antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology1998; 51: 558. Google Scholar 6 : Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol1999; 162: 1346. Link, Google Scholar 7 : The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol1998; 159: 1238. Link, Google Scholar 8 : Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol1998; 160: 2407. Link, Google Scholar 9 : Free, complexed, and total serum prostate-specific-antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology1996; 48: 240. Google Scholar 10 : The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology1995; 46: 773. Google Scholar 11 : Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology1996; 48: 33. Google Scholar 12 : In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to a1-antichymotrypsin in blood samples. Urology1996; 48: 81. Google Scholar 13 : Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am1996; 23: 651. Google Scholar 14 : Anatomic considerations in carcinoma of the prostate. Urol Clin North Am1989; 16: 623. Google Scholar 15 : Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol1974; 111: 58. Abstract, Google Scholar 16 : Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol1992; 148: 331. Link, Google Scholar 17 : Prostate-specific antigen: current status. CA Cancer J Clin1999; 49: 264. Google Scholar 18 : Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology1997; 49: 379. Google Scholar 19 : A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol1996; 156: 350. Link, Google Scholar 20 : Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology1999; 53: 581. Google Scholar 21 : Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol1997; 158: 2188. Link, Google Scholar From the Departments of Urologic Surgery, Pathology and Preventative Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySalem S, Chang S, Clark P, Davis R, Herrell S, Kordan Y, Wills M, Shappell S, Baumgartner R, Phillips S, Smith J, Cookson M and Barocas D (2018) Comparative Analysis of Whole Mount Processing and Systematic Sampling of Radical Prostatectomy Specimens: Pathological Outcomes and Risk of Biochemical RecurrenceJournal of Urology, VOL. 184, NO. 4, (1334-1340), Online publication date: 1-Oct-2010.HAESE A, GRAEFEN M, STEUBER T, BECKER C, NOLDUS J, ERBERSDOBLER A, HULAND E, HULAND H and LILJA H (2018) Total and Gleason Grade 4/5 Cancer Volumes are Major Contributors of Human Kallikrein 2, Whereas Free Prostate Specific Antigen is Largely Contributed by Benign Gland Volume in Serum From Patients With Prostate Cancer or Benign Prostatic BiopsiesJournal of Urology, VOL. 170, NO. 6, (2269-2273), Online publication date: 1-Dec-2003.GRAEFEN M, KARAKIEWICZ P, CAGIANNOS I, HAMMERER P, HAESE A, PALISAAR J, HULAND E, SCARDINO P, KATTAN M and HULAND H (2018) PERCENT FREE PROSTATE SPECIFIC ANTIGEN IS NOT AN INDEPENDENT PREDICTOR OF ORGAN CONFINEMENT OR PROSTATE SPECIFIC ANTIGEN RECURRENCE IN UNSCREENED PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMYJournal of Urology, VOL. 167, NO. 3, (1306-1309), Online publication date: 1-Mar-2002. Volume 165Issue 2February 2001Page: 455-458 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsprostateneoplasmsprostate-specific antigenMetricsAuthor Information DAVID J. GROSSKLAUS More articles by this author SCOTT B. SHAPPELL More articles by this author SHIVA GAUTAM More articles by this author JOSEPH A. SMITH Financial interest and/or other relationship with Astra-Zeneca, TAP Pharmaceuticals, Anthra, Pharmacia, Glaxo, Praecis and Abbott. More articles by this author MICHAEL S. COOKSON More articles by this author Expand All Advertisement PDF downloadLoading ...